디지털 중합효소 연쇄반응 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the global digital pCR market size is expected to grow from USD 0.82 billion in 2025 to USD 0.93 billion in 2026 and is forecast to reach USD 1.86 billion by 2031 at 14.78% CAGR over 2026-2031.

This report is Segmented by Component (Digital PCR Instruments [Droplet-Based Platforms, and More], Consumables and Reagents, and More), by Technology (Droplet Digital PCR, and More), by Application (Clinical Diagnostics [Oncology, and More], Research [Gene Expression Analysis, and More], and More), by End-User (Hospitals and Clinical Laboratories, and More), by Geography (North America, Europe, and More).

Global Digital Polymerase Chain Reaction Market Trends and Insights

Precision Oncology Push for Liquid Biopsy-Ready Assays

Digital PCR platforms now detect circulating-tumor DNA at clinically actionable levels, enabling oncologists to monitor metastatic disease in real time without invasive tissue sampling. Multicenter European standardization covering 93 institutions confirms that assay protocols are mature enough for routine adoption. Research from MIT indicates that primer-based enrichment can further amplify ctDNA signals by 60-fold, reducing false-negative rates and widening the eligible patient base for liquid biopsy monitoring. Together, these gains shift digital PCR from an exploratory research tool toward a reimbursable frontline diagnostic in precision oncology.

Growing Global AMR Surveillance Programs Using Absolute Quantification

National public-health agencies integrate digital PCR into wastewater-testing grids because the technology quantifies resistant organisms even in heavily diluted environmental matrices. European consortia now require dual testing pipelines that pair digital PCR with whole-genome sequencing, ensuring rapid quantification followed by detailed resistance profiling. Australian and New Zealand laboratories reported higher inter-laboratory comparability once standardized digital PCR protocols replaced lab-developed qPCR methods. As urban wastewater programs expand, demand rises for reagent cartridges that maintain analytical consistency across thousands of daily samples.

High Capital & Per-Sample Reagent Costs

Instrument entry prices start around USD 38,000 and escalate when annual maintenance, proprietary consumables and specialized staff training are included. Even though new reagent bundles consolidate up to five assays into one run and cut costs by 43%, the total per-test expense still exceeds high-throughput qPCR by 2-3 times in community hospitals. Start-ups often raise nine-figure venture rounds to cover the long R&D cycle needed to reach cost parity, underlining the capital intensity that limits rapid geographic expansion. Emerging-market budgets therefore prioritize multipurpose hematology or chemistry analyzers unless vendors introduce tiered pricing or reagent-rental schemes.

Other drivers and restraints analyzed in the detailed report include:

1. Decentralization of Molecular Testing Through Compact Benchtop dPCR
2. Mainstream Reimbursement Approvals in US and EU
3. Throughput Limitations vs. qPCR & NGS for Population-Scale Testing

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Consumables & Reagents dominated revenue in 2025, holding 67.35% of the digital PCR market share as recurring kit purchases underpin vendor profitability. This leadership stems from specialized droplet-stabilizing chemistries that laboratories must replenish daily; no generic substitutes meet validation requirements for regulated assays. Consumable demand rises further as wastewater epidemiology and decentralized oncology centers schedule multi-run workflows, stimulating bulk-purchase agreements that increase order visibility for suppliers. Innovation also surges: the 2025 Vericheck ddPCR Empty-Full Capsid Kit delivers dual-parameter AAV assessments in one assay, streamlining cell-therapy lot release timetables and expanding addressable use cases in advanced therapies.

Software & Services, though beginning from a smaller base, will expand at a 14,14% CAGR through 2031, propelled by laboratories that want end-to-end genomic data management. Cloud platforms that integrate sample tracking, assay parameters and HIPAA-compliant result reporting match new IVDR data-integrity rules without heavy on-premises IT investments. As a result, software subscriptions offer vendors an annuity revenue stream that cushions cyclicality in capital-equipment purchases. In clinical contexts, audit-trail functionality aligns with FDA 21 CFR Part 11 mandates, lowering compliance hurdles and accelerating assay validation cycles. By 2031, cloud analytics bundled with instrument leases could become a default procurement model, fostering tighter customer lock-in while improving lab productivity.

Droplet systems maintained 64.78% revenue share of the digital PCR market in 2025, largely because the format delivers up to 20,000 oil-encapsulated partitions that drive statistical precision without complex microfabrication. Early mover Bio-Rad capitalized on a decade of peer-reviewed validation studies, easing buyer concerns related to analytical performance. Industrial users appreciate the straightforward droplet workflow to quantify vector genomes, residual host-cell DNA and low-copy viral contaminants. Yet the architecture's dependence on oil-water emulsification introduces consumable overhead and chemical waste that some sustainability programs flag for reduction.

Microfluidic chip platforms will post a 15.50% CAGR by machining microchambers directly into glass or polymer substrates, eliminating oil suspensions and reducing reagent volume per reaction. Nanomaterial coatings improve amplification efficiency and fluidic control, enabling point-of-care cartridges that consolidate sample prep, amplification and readout inside credit-card-sized cassettes. The architecture also lends itself to parallelization; chips with 5,000 to 10,000 microreactors process multiple patient samples simultaneously while preserving single-molecule sensitivity. Capital spending shifts as microfluidic readers cost about 30% less than traditional droplet generators, making entry feasible for first-time purchasers in middle-income economies. Although droplet systems remain entrenched in high-volume oncology labs, microfluidics attracts new users needing portability and lower per-sample cost.

Complete Report Scope:

• By Component
  • Digital PCR Instruments
    • Droplet-based Platforms
    • Chip-based Platforms
  • Consumables & Reagents
  • Software & Services
• By Technology
  • Droplet Digital PCR (ddPCR)
  • BEAMing Digital PCR
  • Microfluidic Digital PCR
• By Application
  • Clinical Diagnostics
    • Oncology
    • Infectious Disease Testing
    • Genetic Disorders
  • Research
    • Gene Expression Analysis
    • Copy Number Variation
  • Forensics
  • Other Applications
• By End-user
  • Hospitals & Clinical Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America dominated in 2025 by capturing 43.10% of digital PCR market share on the strength of payer reimbursement policies, FDA companion-diagnostic approvals and a USD 2 billion life-sciences capacity expansion by Ther-mo Fisher through 2028. The region's academic-medical centers channel NIH precision-medicine grants directly into instrument procurement, while commercial laboratories negotiate reagent standing orders that secure volume discounts. Suppliers consequently prioritize North-American regulatory clearances, releasing oncology and transplant assays in the U.S. market a full year before global rollout. As a result, digital PCR market size in North America is projected to retain lead status throughout the forecast window.

Asia-Pacific will post the highest regional CAGR at 18.92%, reflecting China's provincial funding for genomics infrastructure and India's aggressive private-sector investments in NABL-accredited clinical labs. Policy initiatives under China's Healthy China 2030 blueprint earmark funding for advanced molecular diagnostics, while local manufacturers collaborate with global vendors to localize reagent production and lower costs. Japan and South Korea supplement regional momentum by integrating digital PCR into national cancer screening pilots and rare-disease newborn tests. Government tenders that bundle instruments with multiyear reagent contracts accelerate market accession for first-time buyers. Europe maintains steady expansion as the IVDR standardizes performance-evaluation dossiers for molecular diagnostics across the bloc. Germany, France and the United Kingdom constitute tri-core demand clusters where biopharma hubs and well-funded health systems adopt digital PCR in oncology centers and central laboratories. Emerging EU economies leverage Cohesion-policy funds to modernize diagnostic infrastructure, often selecting microfluidic platforms that minimize reagent consumption. Meanwhile, Middle East & Africa and South America display early-stage adoption curves with pilot projects in tertiary hospitals and public-health institutes that could transition to full procurement cycles once cost barriers ease.

1. Bio-Rad Laboratories
2. Thermo Fisher Scientific
3. QIAGEN
4. Sysmex
5. Danaher
6. Merck
7. Agilent Technologies
8. Standard BioTools
9. Takara Bio
10. Meridian Bioscience
11. JN Medsys
12. Stilla Technologies
13. Avance Biosciences
14. RainDance Technologies
15. Analytik Jena GmbH
16. Combinati Inc.
17. NIPD Genetics
18. Quantabio
19. Precigenome LLC.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Precision Oncology Push for Liquid Biopsy-Ready Assays
  • 4.2.2 Growing Global AMR Surveillance Programs Using Absolute Quantification
  • 4.2.3 Decentralization of Molecular Testing Through Compact Benchtop dPCR
  • 4.2.4 Mainstream Reimbursement Approvals in U.S. & EU (e.g., Medicare, NICE)
  • 4.2.5 Biopharma Shift To Cell & Gene Therapy Potency Tests (CAR-T, AAV)
  • 4.2.6 Expansion Of Wastewater-Based Epidemiology Post-Covid-19
• 4.3 Market Restraints
  • 4.3.1 High Capital & Per-Sample Reagent Costs
  • 4.3.2 Throughput Limitations Vs. qPCR & NGS for Population-Scale Testing
  • 4.3.3 Scarcity of Regulatory-Cleared IVD Test Menus Beyond Oncology
  • 4.3.4 IP Fragmentation Slowing Cross-Platform Kit Compatibility
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Component
  • 5.1.1 Digital PCR Instruments
    • 5.1.1.1 Droplet-based Platforms
    • 5.1.1.2 Chip-based Platforms
  • 5.1.2 Consumables & Reagents
  • 5.1.3 Software & Services
• 5.2 By Technology
  • 5.2.1 Droplet Digital PCR (ddPCR)
  • 5.2.2 BEAMing Digital PCR
  • 5.2.3 Microfluidic Digital PCR
• 5.3 By Application
  • 5.3.1 Clinical Diagnostics
    • 5.3.1.1 Oncology
    • 5.3.1.2 Infectious Disease Testing
    • 5.3.1.3 Genetic Disorders
  • 5.3.2 Research
    • 5.3.2.1 Gene Expression Analysis
    • 5.3.2.2 Copy Number Variation
  • 5.3.3 Forensics
  • 5.3.4 Other Applications
• 5.4 By End-user
  • 5.4.1 Hospitals & Clinical Laboratories
  • 5.4.2 Academic & Research Institutes
  • 5.4.3 Pharmaceutical & Biotechnology Companies
  • 5.4.4 Contract Research Organizations
  • 5.4.5 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Bio-Rad Laboratories Inc.
  • 6.3.2 Thermo Fisher Scientific Inc.
  • 6.3.3 QIAGEN N.V.
  • 6.3.4 Sysmex Corporation
  • 6.3.5 Danaher Corporation (Cepheid)
  • 6.3.6 Merck KGaA
  • 6.3.7 Agilent Technologies Inc.
  • 6.3.8 Standard BioTools
  • 6.3.9 Takara Bio Inc.
  • 6.3.10 Meridian Bioscience
  • 6.3.11 JN Medsys
  • 6.3.12 Stilla Technologies
  • 6.3.13 Avance Biosciences
  • 6.3.14 RainDance Technologies
  • 6.3.15 Analytik Jena GmbH
  • 6.3.16 Combinati Inc.
  • 6.3.17 NIPD Genetics
  • 6.3.18 Quantabio
  • 6.3.19 Precigenome LLC.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment